Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category ...
Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...
Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a ...
OXB, an Oxford-based cell and gene therapy CDMO (contract development and manufacturing organisation), has reported strong half-year results. The firm posted revenues of £73.2m for the six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results